The company issued a PR today noting Dr. Ross' presentation at this conference. His presentation, "Update on Intralesional Ablative Therapies," is scheduled to begin at 1:55 p.m. ET. Included in his discussion will be information about PV-10's Phase 2 studies, for which he is a Principal Investigator.
Craig is quoted in the PR as: "We expect Dr. Ross's presentation will give additional information about the Phase 2 trial of PV-10 for metastatic melanoma, and specifically, its systemic effect." Could this additional information be about or related to PV-10's effect on visceral metastases? Ross' update comes on the heels of the release of Moffitt's initial work last month: "...PV-10 chemoablation of melanoma lesions leads to a systemic response and the induction of systemic anti-tumor immunity." (PR)
Dr. Argawala first presented information on Phase 2 visceral metastases at a company meeting/presentation for investors at ASCO 2010:
No comments:
Post a Comment